REPLIGEN CORP Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
REPLIGEN CORP (RGEN) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $132.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-07-29
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $66.00M.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $66.00M.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $0.00.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $102.32M.
- REPLIGEN CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $66.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $132.00M 10-Q · filed 2026-07-29 | ||||||
| 2026-03-31 | $66.00M 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | $102.32M 10-K · filed 2026-02-26 | |||||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-14 | |||||||
| 2021-12-31 | $0.00 10-K/A · filed 2024-11-18 | |||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $2.75M derived: sum of 2 quarters · filed 2020-02-26 | $12.20M derived: sum of 3 quarters · filed 2020-02-26 | $19.60M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $12.20M derived: sum of 2 quarters · filed 2018-11-01 | $19.60M 10-Q · filed 2018-11-01 | $23.30M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $16.85M 10-Q · filed 2018-08-02 | $20.55M derived: sum of 3 quarters · filed 2019-03-01 | $26.15M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $7.40M 10-Q · filed 2018-05-08 | $11.10M derived: sum of 2 quarters · filed 2019-03-01 | $16.70M derived: sum of 3 quarters · filed 2019-03-01 | $25.20M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $9.30M derived: sum of 2 quarters · filed 2019-03-01 | $17.80M derived: sum of 3 quarters · filed 2019-03-01 | $23.40M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $14.10M derived: sum of 2 quarters · filed 2017-11-09 | $19.70M 10-Q · filed 2017-11-09 | $29.02M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | $8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $14.10M 10-Q · filed 2017-08-03 | $23.42M derived: sum of 3 quarters · filed 2018-02-22 | $31.33M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $5.60M 10-Q · filed 2017-05-04 | $14.92M derived: sum of 2 quarters · filed 2018-02-22 | $22.83M derived: sum of 3 quarters · filed 2018-02-22 | $28.35M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $17.23M derived: sum of 2 quarters · filed 2018-02-22 | $22.75M derived: sum of 3 quarters · filed 2018-02-22 | $27.59M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $7.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $13.43M derived: sum of 2 quarters · filed 2016-11-03 | $18.26M 10-Q · filed 2016-11-03 | $22.95M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $5.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $10.36M 10-Q · filed 2016-08-04 | $10.36M 10-Q · filed 2015-08-06 | $15.05M derived: sum of 3 quarters · filed 2017-02-23 | $20.67M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $4.84M 10-Q · filed 2016-05-05 | $4.84M 10-Q · filed 2015-05-08 | $9.53M derived: sum of 2 quarters · filed 2017-02-23 | $15.15M derived: sum of 3 quarters · filed 2017-02-23 | $29.11M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $10.31M derived: sum of 2 quarters · filed 2017-02-23 | $24.27M derived: sum of 3 quarters · filed 2017-02-23 | $34.80M 10-K · filed 2017-02-23 | $34.80M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $19.59M derived: sum of 2 quarters · filed 2015-11-05 | $30.12M 10-Q · filed 2015-11-05 | $30.12M 10-Q · filed 2014-11-07 | $39.43M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $13.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $24.49M 10-Q · filed 2015-08-06 | $33.81M derived: sum of 3 quarters · filed 2016-02-25 | $40.32M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $10.53M 10-Q · filed 2015-05-08 | $19.84M derived: sum of 2 quarters · filed 2016-02-25 | $26.36M derived: sum of 3 quarters · filed 2016-02-25 | $33.93M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $15.83M derived: sum of 2 quarters · filed 2016-02-25 | $23.40M derived: sum of 3 quarters · filed 2016-02-25 | $29.21M 10-K · filed 2016-02-25 | $29.21M 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $6.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $14.08M derived: sum of 2 quarters · filed 2014-11-07 | $19.89M 10-Q · filed 2014-11-07 | $26.24M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-06-30 | $7.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $13.38M 10-Q · filed 2014-08-11 | $19.73M derived: sum of 3 quarters · filed 2015-03-17 | $32.11M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-03-31 | $5.81M 10-Q · filed 2014-05-09 | $12.16M derived: sum of 2 quarters · filed 2015-03-17 | $24.54M derived: sum of 3 quarters · filed 2015-03-17 | $34.64M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2012-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $18.73M derived: sum of 2 quarters · filed 2015-03-17 | $28.83M derived: sum of 3 quarters · filed 2015-03-17 | $43.21M 10-K · filed 2015-03-17 | ||||
| 2012-09-30 | $12.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $22.48M derived: sum of 2 quarters · filed 2013-11-08 | $36.86M 10-Q · filed 2013-11-08 | |||||
| 2012-06-30 | $10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $24.48M 10-Q · filed 2013-08-07 | ||||||
| 2012-03-31 | $14.38M 10-Q · filed 2013-05-07 | |||||||
| 2011-12-31 | $45.62M 10-K · filed 2014-03-14 | |||||||
| 2011-09-30 | $18.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $38.68M derived: sum of 2 quarters · filed 2012-11-08 | $68.10M 10-Q · filed 2012-11-08 | |||||
| 2011-06-30 | $20.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $49.84M 10-Q · filed 2012-08-09 | ||||||
| 2011-03-31 | $29.43M 10-Q · filed 2012-05-10 | $83.65M 10-K · filed 2013-03-15 | ||||||
| 2010-12-31 | $54.23M 10-K · filed 2014-03-14 | |||||||
| 2010-03-31 | $59.34M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |